These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18550412)

  • 1. Aseptic osteomyelitis responding to TNFalpha antagonist therapy in a patient with Crohn's disease.
    Bret J; Lemaire O; Prat C; Zabraniecki L; Fournie B
    Joint Bone Spine; 2008 Jul; 75(4):489-91. PubMed ID: 18550412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-TNFalpha therapy in a rare case of Crohn's disease: still a panacea.
    Verburg R; Zelissen P; Rothova A; Siersema PD; Oldenburg B
    Inflamm Bowel Dis; 2008 Oct; 14(10):1457-60. PubMed ID: 18383178
    [No Abstract]   [Full Text] [Related]  

  • 3. Secondary amyloidosis in a patient with long duration Crohn's disease treated with infliximab.
    Fidalgo C; Calado J; Cravo M
    BioDrugs; 2010 Dec; 24 Suppl 1():15-7. PubMed ID: 21175229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease.
    Behm BW; Bickston SJ
    Cochrane Database Syst Rev; 2008 Jan; (1):CD006893. PubMed ID: 18254120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of ankylosing spondylitis and Crohn's disease successfully treated with infliximab.
    Rebelo A; Leite S; Cotter J
    BioDrugs; 2010 Dec; 24 Suppl 1():37-9. PubMed ID: 21175236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of severe perianal disease in Crohn's disease under treatment with infliximab: successful treatment with adalimumab and setons drainage.
    Tursi A; Papa A; Maiorano M
    Inflamm Bowel Dis; 2011 Feb; 17(2):676-8. PubMed ID: 20848475
    [No Abstract]   [Full Text] [Related]  

  • 8. The management of fistulizing oral Crohn's disease with infliximab.
    Staines KS; Green R; Felix DH
    J Oral Pathol Med; 2007 Aug; 36(7):444-6. PubMed ID: 17617840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab therapy in a patient with refractory ileocolic Crohn's disease and Takayasu arteritis.
    Calderón R; Estrada S; Ramírez de la Piscina P; Salvador M; Zabaleta S; Enciso C; Delgado E; García-Campos F
    Rev Esp Enferm Dig; 2010 Feb; 102(2):145-6. PubMed ID: 20361852
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
    de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
    Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined approach with biologics and surgery for enterocutaneous fistulas in Crohn's disease.
    Fries W; La Malfa G; Costantino G; Repici A; Mazziotti S; Navarra G
    Inflamm Bowel Dis; 2011 Feb; 17(2):671-3. PubMed ID: 20848472
    [No Abstract]   [Full Text] [Related]  

  • 12. Adalimumab as second line anti-tumour necrosis factor alpha therapy for Crohn's disease: A single centre experience.
    Sprakes MB; Hamlin PJ; Warren L; Greer D; Ford AC
    J Crohns Colitis; 2011 Aug; 5(4):324-31. PubMed ID: 21683302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ineffectiveness of infliximab therapy in severe infantile Crohn's disease.
    Uslu N; Usta Y; Saltik-Temizel IN; Demir H; Gürakan F; Ozen H; Yüce A
    J Crohns Colitis; 2010 Feb; 4(1):106-9. PubMed ID: 21122492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infliximab-induced acute hepatitis during Crohn's disease therapy: absence of cross-toxicity with adalimumab.
    Haennig A; Bonnet D; Thebault S; Alric L
    Gastroenterol Clin Biol; 2010 Sep; 34(8-9):e7-8. PubMed ID: 20189334
    [No Abstract]   [Full Text] [Related]  

  • 15. Commentary: infliximab or adalimumab in Crohn's disease?
    Sprakes MB; Hamlin PJ
    Aliment Pharmacol Ther; 2012 Aug; 36(4):398. PubMed ID: 22803644
    [No Abstract]   [Full Text] [Related]  

  • 16. Letter: infliximab and adalimumab in the management of Crohn's disease--are they really comparable?
    Lopez-Sanroman A; Gisbert JP
    Aliment Pharmacol Ther; 2012 Sep; 36(5):498-9. PubMed ID: 22860615
    [No Abstract]   [Full Text] [Related]  

  • 17. Treatment with infliximab in a patient with ankylosing spondylitis and Crohn's disease.
    Rednic S; Marinescu C; Chira R; Rogojan L; Rednic N
    J Gastrointestin Liver Dis; 2006 Dec; 15(4):379-82. PubMed ID: 17205151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Anti-TNF therapy in treatment of luminal Crohn's disease].
    Marko B; Prka L
    Acta Med Croatica; 2013 Apr; 67(2):179-89. PubMed ID: 24471301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Letter: are infliximab and adalimumab similar for Crohn's disease in clinical practice?
    Tursi A; Elisei W; Picchio M; Penna A
    Aliment Pharmacol Ther; 2013 Apr; 37(7):763-4. PubMed ID: 23458543
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of metastatic Crohn's disease of the skin while on anti-TNF biologics.
    Patel AV; Jones DM; Hill JC; MacDermott RP
    Inflamm Bowel Dis; 2012 Jun; 18(6):1188-90. PubMed ID: 22294342
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.